Du Jiangxia, Shen Minhui, Chen Jiajia, Yan Hao, Xu Zhifei, Yang Xiaochun, Yang Bo, Luo Peihua, Ding Kefeng, Hu Yuhuai, He Qiaojun
Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Front Pharmacol. 2025 Jan 9;15:1510080. doi: 10.3389/fphar.2024.1510080. eCollection 2024.
Carbohydrates, lipids, bile acids, various inorganic salt ions and organic acids are the main nutrients or indispensable components of the human body. Dysregulation in the processes of absorption, transport, metabolism, and excretion of these metabolites can lead to the onset of severe metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, gout and hyperbilirubinemia. As the second largest membrane receptor supergroup, several major families in the solute carrier (SLC) supergroup have been found to play key roles in the transport of substances such as carbohydrates, lipids, urate, bile acids, monocarboxylates and zinc ions. Based on common metabolic dysregulation and related metabolic substances, we explored the relationship between several major families of SLC supergroup and metabolic diseases, providing examples of drugs targeting SLC proteins that have been approved or are currently in clinical/preclinical research as well as SLC-related diagnostic techniques that are in clinical use or under investigation. By highlighting these connections, we aim to provide insights that may contribute to the development of improved treatment strategies and targeted therapies for metabolic disorders.
碳水化合物、脂质、胆汁酸、各种无机盐离子和有机酸是人体的主要营养物质或不可或缺的组成部分。这些代谢物在吸收、运输、代谢和排泄过程中的失调会导致严重代谢紊乱的发生，如2型糖尿病、非酒精性脂肪性肝病、痛风和高胆红素血症。作为第二大膜受体超家族，溶质载体（SLC）超家族中的几个主要家族已被发现，在碳水化合物、脂质、尿酸盐、胆汁酸、单羧酸和锌离子等物质的运输中起关键作用。基于常见的代谢失调和相关代谢物质，我们探讨了SLC超家族几个主要家族与代谢疾病之间的关系，列举了已获批或目前正在进行临床/临床前研究的靶向SLC蛋白的药物实例，以及正在临床使用或研究中的SLC相关诊断技术。通过强调这些联系，我们旨在提供一些见解，可能有助于开发改进的治疗策略和针对代谢紊乱的靶向治疗方法。
